Compare American International Group Inc (AIG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American International Group Inc vs Viatris Inc — how do they compare? American International Group Inc trades at $77.14 (market cap $40.42B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: American International Group Inc is far larger — about 2.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| AIG | VTRS | |
|---|---|---|
Market Cap | $40.42B | $18.69B |
Sector | Financials | Health |
52-Week High | $86.59 | $17.86 |
52-Week Low | $71.89 | $9.49 |
Enterprise Value | $48.06B | $30.80B |
Dividend Yield | 2.59% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $77.61, down 1.49% today, with a bearish technical signal but strong fundamental performance. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $2.00 exceeding the $1.92 estimate. The company maintains solid profitability with an 11.12% net income margin and a P/E of 14.11, indicating reasonable valuation. Cash flow from operations remains positive at $3.31 billion for 2025, supporting dividend payments of $0.50 per share.
The outlook is mixed; analyst consensus is a Buy with a $89.00 price target, suggesting 14.7% upside, but technical indicators signal near-term caution. Risks include competitive pricing pressure and geopolitical exposures, while opportunities lie in disciplined underwriting and AI integration. Investor sentiment is cautiously optimistic amid steady premium growth and expense control.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
